Format

Send to

Choose Destination
Br J Haematol. 2016 Oct;175(1):77-86. doi: 10.1111/bjh.14196. Epub 2016 Jul 5.

Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.

Author information

1
Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. jorgej_castillo@dfci.harvard.edu.
2
Hospital Universitario de Salamanca, Salamanca, Spain.
3
Department of Haematology, Theageneion Hospital of Thessaloniki, Thessaloniki, Greece.
4
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
5
La Miletrie Hospital, CHU Poitiers, Poitiers, France.
6
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
7
Amyloidosis Research and Treatment Centre, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
8
Department of Haematology, UMC Utrecht Cancer Centre, Utrecht, the Netherlands.
9
Division of Haematology, Niguarda Ca' Granda Hospital, Milano, Italy.
10
St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
11
Service d'Hématologie-Immunologie-Cytogénétique, Centre Hospitalier de Valenciennes, Valenciennes, France.
12
Department of Oncology, Baylor Charles A Sammons Cancer Center, Dallas, TX, USA.
13
Department of Haematology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia.
14
Department of Haematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
15
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
16
Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Abstract

The diagnosis of Waldenström macroglobulinaemia (WM) can be challenging given the variety of signs and symptoms patients can present. Furthermore, once the diagnosis of WM is established, the initial evaluation should be thorough as well as appropriately directed. During the 8th International Workshop for WM in London, United Kingdom, a multi-institutional task force was formed to develop consensus recommendations for the diagnosis and initial evaluation of patients with WM. In this document, we present the results of the deliberations that took place to address these issues. We provide recommendations for history-taking and physical examination, laboratory studies, bone marrow aspiration and biopsy analysis and imaging studies. We also provide guidance on the initial evaluation of special situations, such as anaemia, hyperviscosity, neuropathy, Bing-Neel syndrome and amyloidosis. We hope these recommendations serve as a practical guidance to clinicians taking care of patients with a suspected or an established diagnosis of WM.

KEYWORDS:

Bing-Neel syndrome; Waldenström macroglobulinaemia; amyloidosis; anaemia; hyperviscosity; neuropathy

PMID:
27378193
PMCID:
PMC5154335
DOI:
10.1111/bjh.14196
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

JJC received honoraria from Celgene and Pharmacyclics, and research funding from Abbvie, Gilead, Millennium and Pharmacyclics. RGS received honoraria from Bristol-Myers Squibb, Janssen and Takeda and. EH received honoraria from Amgen, Gilead and Janssen. GM received honoraria from GlaxoSmithKline, Janssen and Millennium-Takeda. RGO received honoraria from Celgene, Janssen, Pharmacyclics and Roche, and research funding from Celgene. CT received honoraria and research funding from Janssen and Roche. MAD received honoraria from Amgen, Celgene, Janssen and Novartis. SPT received research funding and/or honoraria from Gilead, Janssen, Onyx and Pharmacyclics. EK received honoraria from Amgen, Janssen and Takeda and. RAK, XL, MM, MCM, EM, SP, MJS, MV have no conflict of interest to disclose.

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center